UPDATE: Piper Jaffray Lowers PT on Integra Following Anasco Recall

Loading...
Loading...
Piper Jaffray published a report Thursday, as analyst Matt Miksic remained his Neutral rating on Integra LifeSciences Holdings Corp.
IART
while lowering its price target from $46 to $41. Miksic wrote, "Integra's voluntary recall leaves a significant mark on projected results for Q1 and Q2, however, we believe it will prove to be temporary in nature and represents a prudent approach to the company's remediation efforts. Given the company's findings during its internal quality assurance assessment, management opted to err on the side of conservatism in initiating its recall of these additional lots of collagen-based products, which we believe substantially reduces the risk of additional downstream field actions. That said, the recall is the third or fourth FDA- or quality-related announcement in the last 18 months, potentially raising concerns among investors as to when the company will be able to concentrate more of its management and operating resources on driving the business. We expect management to provide greater detail and color on this subject on May 2. We remain Neutral on IART for now, lowering our target from $46 to $41." Integra closed Wednesday at $33.75.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsPiper Jaffray & Co.
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...